MedPath

Temporal Interference and Depression

Not Applicable
Recruiting
Conditions
Major Depressive Disorder
Interventions
Device: Sham stimulation
Device: Temporal Interference stimulation
Registration Number
NCT05295888
Lead Sponsor
Unity Health Toronto
Brief Summary

Major Depressive Disorder (MDD) has a high prevalence, is the leading cause of disability, and currently available interventions are associated with side effects and high treatment resistance. There is an urgent need for the development of novel interventions for MDD with alternate mechanisms of action. Temporal Interference (TI) stimulation is a newly emerging form of transcranial alternating current stimulation (tACS) that involves the application of two high-frequency currents at slightly different kHz frequencies. Since neurons, due to their intrinsic low-pass filtering, do not respond to high frequencies (i.e. \> 100 Hz), TI relies on the 'beat' interaction leading to neuromodulation at any given location, resulting in a much smaller focus and allowing for better targeting. The subgenual cingulate cortex (SCC) appears to be critical in the pathophysiology of depression and treatment response, especially in treatment-resistant cases. Non-invasive treatments, however, are not able to accurately target SCC due to its deep location within the brain. In this trial, 30 participants meeting the diagnostic criteria for MDD will be randomized to receive 10 sessions of 130 Hz TI delivered daily for 30 minutes, or 10 sessions of sham stimulation. During the stimulation, participants will be watching emotional film clips to enhance target engagement. The investigators will collect metrics of SCC target engagement using the resting-state fMRI and EEG technologies, and determine feasibility, tolerability, safety, and therapeutic efficacy of TI stimulation in MDD. The results of this trial will inform the TI technology as a therapeutic tool for network-based psychiatric disorders, including MDD, and be vital for the design and development of a large-scale randomized-controlled trial.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Sham ArmSham stimulationSham stimulation (total 2700 sec): ramp-up (30-60 sec) =\> ramp-down (30-60 sec) =\> stimulation (130Hz, 0mA, 2520-2610 sec) =\> ramp-down (30-60 sec)
Experimental ArmTemporal Interference stimulation130Hz TI stimulation (total 2700 sec): ramp-up (30-60 sec) =\> stimulation (130Hz, 2mA per electrode pair, 4mA total, 2580-2640 sec) =\> ramp-down (30-60sec)
Primary Outcome Measures
NameTimeMethod
Neuroimaging - Perfusion metricsEnd of 2nd week of intervention

Cerebral blood flow within SCC to demonstrate SCC target engagement to TI stimulation

Neuroimaging - Signal varianceEnd of 2nd week of intervention

Signal variance within SCC to demonstrate SCC target engagement to TI stimulation

Neuroimaging - Functional connectivityEnd of 2nd week of intervention

Seed-based resting-state functional connectivity of SCC to demonstrate SCC target engagement to TI stimulation

Neuroimaging - Anatomical connectivityEnd of 2nd week of intervention

Anatomical connectivity of SCC to demonstrate SCC target engagement to TI stimulation

Secondary Outcome Measures
NameTimeMethod
Tolerability - Adverse eventsEnd of 1st week of intervention, end of 2nd week of intervention, 1 week post-intervention, and 4 weeks post-intervention

Incidence of treatment-emergent adverse events

Trial Feasibility - Dropout rateEnd of 1st week of intervention, end of 2nd week of intervention, 1 week post-intervention, and 4 weeks post-intervention

The proportion of participants who discontinue participation in the study before completion

Trial Feasibility - Recruitment rateEnrollment

The number of participants enrolled into the study per month

Trial Feasibility - Intervention adherenceEnd of 2nd week of intervention

Percentage of participants who completed ≥80% of scheduled intervention sessions

Clinical change in depression symptomsBaseline, each intervention visit (5 times/week for 2 weeks), 1 week post-intervention, and 4 weeks post-intervention

Change in symptoms of depression measured by the 16-item Quick Inventory of Depressive Symptomatology; scores range from 0 to 48, and higher scores indicate more severe depression symptoms.

EEG Signals - Frequency domain featuresBaseline, end of 1st week of intervention, and end of 2nd week of intervention

Changes in frequency domain features of gamma oscillation on resting-state EEG Changes in frequency domain features of theta oscillation on resting-state EEG

EEG Signals - Functional connectivityBaseline, end of 1st week of intervention, and end of 2nd week of intervention

Changes in functional connectivity on resting-state EEG

Correlation between EEG and depression symptomsBaseline, end of 1st week of intervention, and end of 2nd week of intervention

Correlation between changes in features of gamma or theta oscillations (EEG) and changes in depression symptoms measured by the HAM-D

EEG Signals - MMN event-related potentialBaseline, end of 1st week of intervention, and end of 2nd week of intervention

Changes in mismatch negativity (MMN) event-related potential amplitude and latency

EEG Signals - Time domain featuresBaseline, end of 1st week of intervention, and end of 2nd week of intervention

Changes in time domain features of gamma oscillation on resting-state EEG Changes in time domain features of theta oscillation on resting-state EEG

Trial Locations

Locations (1)

Interventional Psychiatry Program, St. Michael's Hospital - Unity Health Toronto

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath